Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Novartis AG | 960 |
| 2 | Pfizer Inc | 454 |
| 3 | Bayer AG | 376 |
| 4 | Johnson and Johnson | 362 |
| 5 | Roche Holding AG | 327 |
| 6 | Merck and Co Inc | 257 |
| 7 | Takeda Pharmaceutical Co Ltd | 240 |
| 8 | Ipsen SA | 166 |
| 9 | Kymera Therapeutics Inc | 161 |
| 10 | Cartesian Therapeutics Inc | 154 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 11,411 |
| 2 | A61K | Medicinal preparations | 10,660 |
| 3 | C07D | Heterocyclic compounds | 4,630 |
| 4 | C07J | 2,812 | |
| 5 | G01N | Investigating / analysing materials | 2,282 |
| 6 | C12N | Microorganisms, enzymes | 1,703 |
| 7 | C07K | Peptides | 1,468 |
| 8 | C12P | Fermentation, enzyme processes | 1,047 |
| 9 | C12Q | Measuring/testing involving enzymes | 987 |
| 10 | C07C | Acyclic and carbocyclic compounds | 913 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| 4-SUBSTITUTED ANDROSTENDIONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | 1986 | Pfizer Inc | 30 |
| 4-amino androstendione derivatives and process for their preparation | 1988 | Pfizer Inc | 29 |
| Method for preparing androstenedione by biodegradation of phytosterol in two-liquid-phase system | 2009 | 18 | |
| Extraction of 4-androstenedione from oil phase of fermenting liquid | 2005 | 18 | |
| Biofermentation method for androstendione by using resting cell | 2010 | 17 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 87 |
| 2017 | 83 |
| 2018 | 53 |
| 2019 | 67 |
| 2020 | 59 |
| 2021 | 61 |
| 2022 | 87 |
| 2023 | 69 |
| 2024 | 47 |
| 2025 | 20 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Mitch Dowsett | Royal Marsden Hospital | 66 |
| 2 | Frank Z. Stanczyk | University of Southern California | 61 |
| 3 | Fernand Labrie | Université Laval | 39 |
| 4 | R. J. Scaramuzzi | Commonwealth Scientific and Industrial Research Organisation | 33 |
| 5 | L Stárka | Institute of Endocrinology | 28 |
| 6 | Jan-Ακε Gustafsson | Karolinska Institutet | 25 |
| 7 | Mitsuteru Numazawa | Tohoku Medical and Pharmaceutical University | 23 |
| 8 | L. J. Spicer | Oklahoma State University | 22 |
| 9 | Van Luu‐The | Université Laval | 18 |
| 10 | Per Eystein Lønning | Haukeland University Hospital | 18 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer | 2006 | 1085 | Prostate Cancer Treatment and Research |
| Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. | 2002 | 1042 | Ovarian function and disorders |
| Androgen Levels in Adult Females: Changes with Age, Menopause, and Oophorectomy | 2005 | 1000 | Ovarian function and disorders |
| Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. | 1986 | 994 | Sperm and Testicular Function |
| Correlation of Hyperandrogenism with Hyperinsulinism in Polycystic Ovarian Disease* | 1980 | 921 | Ovarian function and disorders |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of androstenedione?
Which companies hold the largest patent portfolios for androstenedione?
What are the most-cited research papers on androstenedione and their primary topics?
Who are the most prolific authors publishing on androstenedione?
What are the dominant patent classifications for androstenedione technology?